These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10430248)

  • 1. A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma.
    Stuart K; Tessitore J; Rudy J; Clendennin N; Johnston A
    Cancer; 1999 Aug; 86(3):410-4. PubMed ID: 10430248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
    Jodrell DI; Bowman A; Rye R; Byrne B; Boddy A; Rafi I; Taylor GA; Johnston A; Clendeninn NJ
    Br J Cancer; 1999 Feb; 79(5-6):915-20. PubMed ID: 10070890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
    Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
    J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma.
    Mok TS; Leung TW; Lee SD; Chao Y; Chan AT; Huang A; Lui MC; Yeo W; Chak K; Johnston A; Johnson P
    Cancer Chemother Pharmacol; 1999; 44(4):307-11. PubMed ID: 10447578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
    Jhawer M; Rosen L; Dancey J; Hochster H; Hamburg S; Tempero M; Clendeninn N; Mani S
    Invest New Drugs; 2007 Feb; 25(1):85-94. PubMed ID: 16957834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymitaq (Zarix).
    Niculescu-Duvaz I
    Curr Opin Investig Drugs; 2001 May; 2(5):693-705. PubMed ID: 11569949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days.
    Hughes AN; Rafi I; Griffin MJ; Calvert AH; Newell DR; Calvete JA; Johnston A; Clendeninn N; Boddy AV
    Clin Cancer Res; 1999 Jan; 5(1):111-8. PubMed ID: 9918208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
    Ikeda M; Okusaka T; Ueno H; Takezako Y; Morizane C
    Cancer; 2005 Feb; 103(4):756-62. PubMed ID: 15637692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation.
    Estlin EJ; Pinkerton CR; Lewis IJ; Lashford L; McDowell H; Morland B; Kohler J; Newell DR; Boddy AV; Taylor GA; Price L; Ablett S; Hobson R; Pitsiladis M; Brampton M; Clendeninn N; Johnston A; Pearson AD
    Br J Cancer; 2001 Jan; 84(1):11-8. PubMed ID: 11139306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
    Uhm JE; Park JO; Lee J; Park YS; Park SH; Yoo BC; Paik SW; Koh KC; Kang WK; Lim HY
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):929-35. PubMed ID: 18726098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1].
    Nagata H; Hatano E; Asechi H; Narita M; Yanagida A; Yasuchika K; Ikai I; Uemoto S
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):233-5. PubMed ID: 17301534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis.
    Wen J; Shen WL; Yang SH
    Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):224-7. PubMed ID: 16698580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.